HIV

The AJMC® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.

Latest News

Black man with HIV | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

July 3rd 2025

Black men who were identified as sexual minorities were more receptive to long-acting injectable pre-exposure prophylaxis (PrEP) vs on-demand PrEP.

PrEP | Image credit: alimyakubov - stock.adobe.com
Higher Levels of PrEP Use Associated With Reduction in HIV Diagnoses

June 30th 2025

PrEP | Image credit: Bowonpat - stock.adobe.com
Researchers Estimate PrEP Needed in the US Across Multiple Subgroups

June 24th 2025

Colleen Kelley, MD, MPH
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH

June 20th 2025

Image credit: Yale School of Medicine
Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA

June 19th 2025

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.
Continuing Medical Education
View All
July 5th 2025

Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence

1.5 Credits / HIV/AIDS, Infectious Diseases
July 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

What We’re Reading: J&J Ends HIV Vaccine Trial; Deaths After Abortion Bans; Sanofi Looks to Hemophilia A Drug
January 19th 2023

What We’re Reading: J&J Ends HIV Vaccine Trial; Deaths After Abortion Bans; Sanofi Looks to Hemophilia A Drug

AJMC Staff
Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
metal spoon holding vitamin D pills
January 4th 2023

Women With HIV More Likely to Get Vitamin D From Supplements, Not Diet

Hayden E. Klein
A study showed that Canadian women living with HIV were less likely to get vitamin D through dairy consumption, but more likely to take vitamin D supplements, compared with women without HIV.
the top 5 HIV content of 2022
December 28th 2022

Top 5 Most-Viewed HIV Content of 2022

Justina Petrullo
This year’s most-viewed HIV content focused on disparities in HIV care, an emerging nonepidemic Kaposi sarcoma subtype, and the need for more research on hepatitis B endurance.
New York City skyline panorama at sunrise
December 22nd 2022

HIV Self-testing Relatively Uncommon Among MSM in Urban Areas

Hayden E. Klein
Of 6563 men who have sex with men (MSM) living in urban areas in 2017, only 7.7% reported HIV self-testing in the past year.
HIV PrEP pill in hand
December 17th 2022

USPSTF Recommends HIV PrEP

Hayden E. Klein
The US Preventive Services Task Force (USPSTF) announced its recommendation for HIV pre-exposure prophylaxis (PrEP).
doctor talking to patient with clipboard on desk
December 15th 2022

Conversations Around HIV PrEP With Adolescents Vary Between Urban, Rural Family Physicians

Hayden E. Klein
This new study shows that family medicine physicians in rural areas tend to be less comfortable in HIV pre-exposure prophylaxis (PrEP)-related clinical activities and conversations with adolescents than those in urban areas.
hundred dollar bills covered by pills
December 7th 2022

ICYMI: Top Highlights From AMCP Nexus 2022

AJMC Staff
Perry N. Halkitis, PhD, MS, MPH
December 1st 2022

Contributor: On World AIDS Day—Lessons Drawn From HIV, Monkeypox, and COVID-19

Perry N. Halkitis, PhD, MS, MPH
Dr Halkitis is currently working on his new book "People, Politics, & Public Health: How the American People Created the HIV, COVID-19, and Other Modern-Day Pandemics," to be published by Johns Hopkins University Press.
HIV Care Should Be Comprehensive, Says Dr Jana Dickter
November 29th 2022

HIV Care Should Be Comprehensive, Says Dr Jana Dickter

Hayden E. Klein Skylar Jeremias
Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, addresses what health systems need to do to improve HIV therapy accessibility and affordability.
graphic of people
November 26th 2022

Social Vulnerability Thought to Impact Diagnosis of HIV and Receival of Care

Justina Petrullo
Communities that are experiencing the most social vulnerability may need stronger preventative measures against HIV and increased levels of HIV care.
Kevin N. Astle, PharmD
November 26th 2022

Dr Kevin Astle: Long-Acting Injectables Are a Game Changer for Adherence

Hayden E. Klein
Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure
November 25th 2022

Triple Therapy Maintains HIV Viral Suppression in Patients With Mutation, Prior Virologic Failure

Hayden E. Klein
According to the study authors, bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) may be an option for simplification following viral suppression.
Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan
November 22nd 2022

Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan

Hayden E. Klein
Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Jana Dickter, MD
November 16th 2022

Stem Cell Transplant May Be Viable Treatment for Patients With HIV, Leukemia, Says Dr Jana Dickter

Hayden E. Klein Skylar Jeremias
Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.
group of people wearing white t shirts and red HIV ribbons
November 3rd 2022

Earlier ART Linked to Better Long-term HIV Outcomes

Hayden E. Klein
An extended follow-up to a 2015 study further supports that beginning antiretroviral therapy (ART) earlier is linked to better long-term outcomes compared with delayed ART initiation.
What We're Reading
October 27th 2022

What We’re Reading: State Determines Health Outcomes; Increasing Comorbid HIV/Monkeypox Infection; More Children Uninsured

AJMC Staff
A recent study found that Americans die younger in states with conservative policies; most patients admitted to the hospital with monkeypox also have HIV; 4 million children are uninsured due to state policies, according to new research.
Kevin Astle, PharmD
October 25th 2022

Dr Kevin Astle on the Pharmacist's Role in PrEP Accessibility, Adherence

Hayden E. Klein
Pharmacists must take time to understand why patients are not adherent to HIV pre-exposure prophylaxis (PrEP) and what barriers exist, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
HIV and Blood Cancers: The City of Hope Patient
October 21st 2022

HIV and Blood Cancers: The City of Hope Patient

Mary Caffrey
A featured presentation at the Irvine, California, meeting of the Institute for Value-Based Medicine discussed how a patient with long-term HIV was cured through a transplant.
Jana K. Dickter, MD
October 19th 2022

Dr Jana Dickter Talks About Developments in HIV Treatment, Management

Hayden E. Klein Skylar Jeremias
HIV antiretroviral therapy has changed and improved dramatically since it first became available, said Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope.
HIV Awareness.
October 14th 2022

Examining Cost-effectiveness, Efficacy of Combination Therapies in HIV

Matthew Gavidia
Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.
Kevin Astle, PharmD
October 13th 2022

Dr Kevin Astle Discusses Therapies in HIV PrEP Pipeline and Trends in Access, Adherence

Hayden E. Klein
Kevin N. Astle, PharmD, assistant professor at University of South Florida Taneja College of Pharmacy, expands on HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline discussed at the Academy of Managed Care Pharmacy Nexus fall 2022 meeting.
David Koren, PharmD
October 6th 2022

Dr David Koren: It's Important for Providers to Empower Patients With HIV

Hayden E. Klein
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, emphasizes the importance of patients with HIV and providers working together.
doctor prepping vaccine
October 4th 2022

Third COVID-19 Vaccine Dose Yields Higher Immune Protection in PLWH

Hayden E. Klein
Results of a study among persons living with HIV (PLWH) in Hong Kong showed that a 3-dose primary COVID-19 vaccine series improved immune protection.
Picture of author M. "Tonette" Krouser-Wood
September 27th 2022

Contributor: Every Day Is HIV Awareness Day—The Importance of Motivating People to Get Tested for HIV

M. "Tonette" Krousel-Wood, MD, MSPH, FACPM
David E. Koren, PharmD, MPH
September 22nd 2022

Dr David Koren Discusses Barriers to Implementing Long-Acting Injectables for HIV

Hayden E. Klein
David E. Koren, PharmD, MPH, BCPS, AAHIVP, FIDSA, infectious disease clinical pharmacist at Temple University Hospital, explains the barriers both patients and providers face in implementing long-acting injectables for HIV.
What We're Reading
September 14th 2022

What We’re Reading: AMA Joins Class-Action Lawsuit; Monkeypox Brain Inflammation; San Francisco HIV Cases

AJMC Staff
The American Medical Association (AMA) and 2 state medical societies joined a class-action lawsuit against Cigna for underpaying claims filed by providers; 2 cases of monkeypox have led to brain inflammation; for the first time, gay and bisexual men make up less than half of new HIV cases in San Francisco.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
September 10th 2022

Dr Anchalee Avihingsanon: We Can Learn About Curing Hepatitis B From Investigating HIV

Maggie L. Shaw
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial, currently evaluating the responses of treatment-naïve persons living with comorbid HIV/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
man filling out survey
September 7th 2022

Survey Reveals Injectable HIV PrEP Preferences of Young Men Who Have Sex With Men

Hayden E. Klein
Young men who have sex with men (YMSM) said the treatment’s efficacy was the most important feature injectable HIV pre-exposure prophylaxis (PrEP), over side effects, cost, protection duration, and delivery method.
Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre
September 3rd 2022

Dr Anchalee Avihingsanon: We Need More Study on Hep B Endurance in PLWH

Maggie L. Shaw
The ALLIANCE trial is investigating the responses of treatment-naïve persons living with comorbid HIV (PLWH)/hepatitis B virus to a triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate.
tablet with video of doctor
September 1st 2022

Tailored Video Doctor Intervention May Benefit Certain PLWH

Hayden E. Klein
A highly tailored video doctor intervention was shown to help men living with HIV achieve viral suppression, and younger and older patients achieve HIV care retention.
<1
...
5678910111213
...
33>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo